September 14, 2026

Consolidated Financial Results for the Fiscal Year Ended July 31, 2026 (Under Japanese GAAP)

Company name: Premier Anti-Aging Co., Ltd.
Listing exchange: Tokyo Stock Exchange
Securities code: 4934
URL: https://www.p-antiaging.co.jp/en
Representative: Kiyoshi Matsuura, President
Inquiries: Yuka Uehara, Executive Officer of Corporate Division
Phone: +81-3-3502-2020
Scheduled date for next annual general shareholders meeting: October 29, 2026
Scheduled date for commencing dividend payments: -
Scheduled date to file annual securities report: October 23, 2026
Preparation of supplementary materials on financial results: Yes
Holding financial results briefing: Yes (for institutional investors and analysts)

(Amounts are rounded down to the nearest million yen, unless otherwise noted)

1. Consolidated financial results for the fiscal year ended July 31, 2026 (from August 1, 2025 to July 31, 2026)

(1) Consolidated operating results

(Percentage figures indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
July 31, 2026	13,883	(14.1)	494	(19.8)	602	0.5	364	(22.8)
July 31, 2025	16,160	(20.6)	617	343.8	599	271.8	471	-

Note: Comprehensive income
Fiscal year ended July 31, 2026: 328 million yen [(30.6) %]
Fiscal year ended July 31, 2025: 473 million yen [- %]

	Basic earnings per share	Diluted earnings per share	Return on equity	Return on assets	Operating profit/ net sales
Fiscal year ended	Yen	Yen	%	%	%
July 31, 2026	41.77	41.77	5.4	5.9	3.6
July 31, 2025	54.10	54.03	7.4	5.7	3.8

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
July 31, 2026	10,244	6,957	67.6	794.33
July 31, 2025	10,140	6,610	65.1	756.65

Reference: Total shareholders' equity
As of July 31, 2026: 6,926 million yen
As of July 31, 2025: 6,598 million yen

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
July 31, 2026	217	(227)	267	4,951
July 31, 2024	1,472	(229)	(1,337)	4,655

2. Cash dividends

	Annual dividends per share					Total cash dividends	Payout ratio (Consolidated)	Dividends to net assets (Consolidated)
	End of first quarter	End of second quarter	End of third quarter	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended July 31, 2025	-	0.00	-	0.00	0.00	-	-	-
Fiscal year ended July 31, 2026	-	0.00	-	0.00	0.00	-	-	-
Fiscal year ending July 31, 2027 (Forecast)	-	0.00	-	0.00	0.00		-	

3. Consolidated earnings forecasts for the fiscal year ending July 31, 2027 (from August 1, 2026 to July 31, 2027)

(Percentage figures indicate year-on-year changes for full year and for six months)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending January 31, 2027	6,750	(8.1)	(50)	-	(50)	-	(50)	-	(5.73)
Full year	13,500	(2.8)	100	(80.0)	100	(83.4)	100	(72.5)	11.47

* Notes

(1) Changes in significant subsidiaries during the fiscal year (changes in specified subsidiaries resulting in change in scope of consolidation): None

(2) Changes in accounting policies, changes in accounting estimates, and restatements

i. Changes in accounting policies due to revisions to accounting standards, etc.: None
ii. Changes in accounting policies other than those in i. above: None
iii. Changes in accounting estimates: None
iv. Restatements: None

(3) Number of shares issued and outstanding (common shares)

i. Number of shares issued and outstanding at the end of the fiscal year (including treasury shares)

As of July 31, 2026	8,720,534 shares
As of July 31, 2025	8,720,534 shares

ii. Number of treasury shares at the end of the fiscal year

As of July 31, 2026	155 shares
As of July 31, 2025	155 shares

iii. Average number of shares outstanding during the fiscal year

Fiscal year ended July 31, 2026	8,720,379 shares
Fiscal year ended July 31, 2025	8,720,379 shares

[Reference] Overview of non-consolidated financial results

1. Non-consolidated financial results for the fiscal year ended July 31, 2026 (from August 1, 2025 to July 31, 2026)

(1) Non-consolidated operating results

(Percentage figures indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
July 31, 2026	10,387	(19.3)	467	11.9	543	25.1	459	4.3
July 31, 2025	12,874	(30.0)	418	-	434	-	440	-

	Basic earnings per share	Diluted earnings per share
Fiscal year ended	Yen	Yen
July 31, 2026	52.65	52.65
July 31, 2025	50.47	50.41

(2) Non-consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
July 31, 2026	8,101	6,795	83.5	775.68
July 31, 2025	8,389	6,317	75.2	723.03

Reference: Total shareholders' equity
As of July 31, 2026: 6,764 million yen
As of July 31, 2025: 6,305 million yen

* The report on financial results is not subject to audit procedures by a certified public accountant or an auditing firm.

* Explanation regarding appropriate use of earnings forecasts, and other notes
(Caution regarding forward-looking statements, etc.)
The earnings outlook and other forward-looking statements contained in this document are based on information currently available to, and certain assumptions that are deemed to be reasonable by the Company. Such statements are not intended as a promise by the Company that they will be achieved. Actual results may differ from the forecasts in this document due to various factors. For the conditions forming the assumptions used in forecasting earnings and precautions regarding the use of earnings forecasts, please refer to “1. Overview of financial results, etc. (4) Future outlook” on page 5 of the Attachment.

Contents of Attachment

1. Overview of financial results, etc.

(1) Overview of financial results for the current fiscal year

In the consolidated fiscal year ended July 31, 2026 (the “current fiscal year”), the Japanese economy continued to recover moderately, despite some signs of slowing down in certain areas. Personal consumption continued on a moderate recovery trend, supported by a favorable income environment and government policies that curbed price increases, as well as a rebound in consumer sentiment driven by factors such as the easing of tensions in the Middle East. While there have been no significant changes in consumer trends within the domestic cosmetics market, the market has remained resilient, supported by rising personal consumption and inbound demand driven by the weak yen.
Under these circumstances, Premier Anti-Aging Co., Ltd. (“the Company”) and its consolidated subsidiaries (“the Group”) aims to bottom out sales in the anti-aging business by further strengthening brand management and collaboration with each channel, and in the recovery business, as a pioneer, aims to further expand its business in a growing market.
During the current fiscal year, sales increased steadily in the recovery business conducted through subsidiary Venex Co., Ltd., but sales in the anti-aging business conducted by the Company decreased, resulting in an overall sales of 13,883 million yen (down 14.1% year on year). On the other hand, operating profit amounted to 494 million yen (down 19.8% year on year), due to lower-than planned selling expenses, mainly advertising expenses related to acquiring new customers in the anti-aging business, and the implementation of appropriate cost management through continued fixed cost reduction. Ordinary profit was 602 million yen (up 0.5% year on year), mainly due to the recording of foreign exchange gains. Profit attributable to owners of parent was 364 million yen (down 22.8% year on year) due to the recording of restructuring costs as an extraordinary loss, resulting from the decision to consolidate the sales system in China into an efficient and high-growth cross-border e-commerce business and to dissolve and liquidate the local subsidiary.

Business results by segment are as follows.
Anti-aging business

(Millions of yen)

	Previous fiscal year (From August 1, 2024 to July 31, 2025)	Current fiscal year (From August 1, 2025 to July 31, 2026)	Year on year change (%)
Net sales	12,926	10,349	(19.9)
Operating profit	408	660	61.5

Net sales
Anti-aging business sales amounted to 10,349 million yen (down 19.9% year on year).
By channel, wholesale sales increased due to strong sales of the revamped “DUO,” but mail order sales fell below the previous period’s figures due to a lack of improvement in the efficiency of advertising for acquiring new customers.
In mail order sales, we are working to strengthen our reach to those who have not yet tried our products and acquire new customers, while also working to introduce new and limited-edition products to increase the average customer spending and promote cross-selling, and further expand our CRM measures. During the current fiscal year, we achieved some success through initiatives such as promotions designed to boost the retention rate of subscription customers, trial campaigns for acquiring new customers using the mini size of “The Cleansing Balm” from “DUO,” and trial set offers containing three skincare products; however, these efforts were insufficient to offset the decline in new customer acquisition, resulting in continued sales decline.
In wholesale sales, we are working to develop new brands exclusively for wholesale sales, secure growth potential through improved collaboration with wholesale clients, and strengthen our e-commerce mall business. During the current fiscal year, following the complete renewal of five types of "The Cleansing Balm" series from "DUO," we continued to promote products in collaboration with wholesale clients, taking advantage of the fact that “The Cleansing Balm Black Repair” won the No. 1 Best Cleansing of @cosme Best Cosmetics Award for Best New Cosmetics for the First Half of 2025. As a result, wholesale sales were performing solidly.

The situation by brand is as follows.
The “DUO” brand's “The Cleansing Balm” series has achieved the No. 1 sales ranking for cleansing balms for eight consecutive years*[1], and the cumulative number of units shipped for the series exceeded 60 million by the end of January 2026. In the mail order business, we conducted trial set offers containing skin care products, providing an opportunity for customers to learn about benefits of “DUO,” while we are also intensifying our efforts to connect with customers through multiple products. In October 2025, we launched the limited-edition “DUO The Cleansing Balm Scrub Black” in collaboration with Pan Pacific International Co., Ltd., and in March 2026, we released the limited-edition “The Cleansing Balm Black Repair [SWEET STEADY Limited Design]” in collaboration with the seven-member idol group “SWEET STEADY” belonging to KAWAII LAB., aiming to strengthen our wholesale sales. The new line from “DUO,” the cleansing serum “DUO Cleanse Serum Peel & Boost” won the third place of the New Product Best Cleansing category of @cosme Best Cosmetics Awards for the First Half of 2026, and has achieved 21 best cosmetics awards in just six months since its official launch in January 2026. With the addition of these new products, we continued to implement communications and promotions that emphasize and spread the brand value. In July 2026, we announced plans to accelerate the full-scale expansion into the skincare sector, centered on the “Skin for Longevity” concept, in pursuit of our corporate purpose; subsequently, in August 2026, we launched “DUO The Cleansing Balm Poreless” and “DUO The Poreless Serum” under the “DUO” brand, featuring a world-first formulation designed to address pore concerns in adults. Going forward, we will continue to introduce new and limited edition products under the “DUO” brand, and implement communication strategies to promote and solidify the brand’s value. We remain focused on reversing the sales trend for the “DUO” brand across both mail order sale and wholesale businesses.
The “CANADEL” brand continues to receive high praise for its products, however, while the rate of decline has slowed, sales continue to fall. In April 2026, we launched “CANADEL Premier Moist Cool,” a popular product specifically designed to address summer skin concerns, exclusively through our official online store, and it has been well received by customers. Moving forward, we will work to revitalize our brand assets while efficiently utilizing our sales promotion budget.
Regarding the “clayence” brand, we launched a renewed version of the “Clay Spa Color Keep & Damage Care Mask,” which addresses the three major hair concerns of adults all in one product. We continue to work on product improvement and development, and aim to develop it into a comprehensive hair care brand.
In addition, “Reinca,” a skincare brand that embraces the concept of recovery beauty for the skin, launched a new product, “Reinca Stem Treatment Recovery Mask,” which contains Reinca's unique stem cell culture extract ENGY Stem S® *[2] and Venex's unique ingredient PHT® (Platinum Harmonized Technology: DPV576) *[3] in April 2026. To mark the launch, we held new product events at department stores in the Tokyo metropolitan area, Kyushu, and Kansai regions, allowing a greater number of customers to experience the Reinca brand. Furthermore, Reinca has received high praise from inbound tourists. We are also continuing test marketing for “Lalaskin,” a skin care brand that embodies the fast beauty medical concept, which was launched as a wholesale exclusive brand, the inner care supplement “SINTO Liposomal Vitamin C” and high-concentration Vitamin C skin care brand “C+mania.”

*[1] Fuji Keizai Co., Ltd., “Cosmetics Marketing Handbook 2026 No. 1, 2025 No. 1, 2021 No. 1,” Cleansing Balm Market Share (Survey period: 2018-2025, sales value)
*[2] Human dental pulp cell conditioned medium (skin conditioning ingredient)
*[3] Colloidal diamond, platinum (skin conditioning ingredient) PHT is a registered trademark of VENEX Co., Ltd. in Japan.

Operating profit
Operating profit amounted to 660 million yen (up 61.5% year on year) due to lower-than planned selling expenses, mainly advertising expenses related to acquiring new customers, and the implementation of appropriate cost management through continued fixed cost reduction.

Recovery business

(Millions of yen)

	Previous fiscal year (From August 1, 2024 to July 31, 2025)	Current fiscal year (From August 1, 2025 to July 31, 2026)	Year on year change (%)
Net sales	3,233	3,533	9.3
Operating profit	208	(165)	-

Net sales

Sales reached 3,533 million yen (up 9.3% year-on-year), driven by steady growth in offline sales at department stores and other retail outlets, including the flagship brand "Standard Dry Plus," as well as "Recovery Cool Plus," a renewed version of the long selling "Comfort Cool," and the entry model "Comfort Punch."

Operating profit

Although gross profit increased along with the growth in sales, operating profit resulted in an operating loss of 165 million yen (operating profit of 208 million yen in the previous fiscal year). This was mainly due to investment in advertising and promotional expenses to raise brand recognition and generate interest, as well as continued organizational strengthening, such as hiring, in anticipation of business growth from next fiscal year onwards.

(2) Overview of financial position at the end of the current fiscal year

Assets, liabilities and net assets at the end of the current fiscal year were as follows.

(Assets)

Total assets at the end of the current fiscal year increased by 104 million yen from the end of the previous fiscal year to 10,244 million yen. The main factors of increase and decrease were as follows.

Current assets increased by 224 million yen from the end of the previous fiscal year to 8,297 million yen.

This was mainly due to an increase of 295 million yen in cash and deposits, a decrease of 249 million yen in accounts receivable - trade, and an increase of 104 million yen in finished goods.

Non-current assets decreased by 120 million yen from the end of the previous fiscal year to 1,947 million yen. This was mainly due to a decrease of 80 million yen in software and a decrease of 41 million yen in goodwill.

(Liabilities)

Total liabilities at the end of the current fiscal year decreased by 243 million yen from the end of the previous fiscal year to 3,287 million yen. The main factors of increase and decrease were as follows.

Current liabilities decreased by 131 million yen from the end of the previous fiscal year to 2,865 million yen. This was mainly due to an increase of 455 million yen in short-term borrowings and a decrease of 245 million yen in accounts payable - other.

Non-current liabilities decreased by 111 million yen from the end of the previous fiscal year to 421 million yen. This was mainly due to a decrease of 67 million yen in long-term borrowings.

(Net Assets)

Net assets at the end of the current fiscal year increased by 347 million yen from the end of the previous fiscal year to 6,957 million yen. This was mainly due to an increase of 364 million yen in retained earnings.

As a result, the equity ratio was 67.6%.

(3) Overview of cash flows at the end of the current fiscal year

Cash and cash equivalents ("net cash") at the end of the current fiscal year amounted to 4,951 million yen (increased by 295 million yen from the end of the previous fiscal year).

The status of cash flows and their factors during the current fiscal year were as follows.

(Cash flows from operating activities)

Net cash provided by operating activities in the current fiscal year amounted to 217 million yen (cash inflow of 1,472 million yen in the previous fiscal year). The major factors of cash inflows were recording profit before income taxes of 337 million yen and a decrease of 249 million yen in trade receivables, while the major factors of cash outflow were

an increase of 266 million yen in inventories and a decrease of 255 million yen in accounts payable - other.
(Cash flows from investing activities)
Net cash used in investing activities in the current fiscal year amounted to 227 million yen (cash outflow of 229 million yen in the previous fiscal year). The major factor of cash inflow was gain on surrender of insurance policy of 13 million yen, while the major factor of cash outflow was purchase of intangible assets of 155 million yen.
(Cash flows from financing activities)
Net cash provided by financing activities in the current fiscal year amounted to 267 million yen (cash outflow of 1,337 million yen in the previous fiscal year). The major factor of cash inflow was an increase of 455 million yen in short-term borrowings, while the major factor of cash outflow was repayments of long-term borrowings of 211 million yen.

(4) Future outlook

Looking to the future, we expect that WTI crude oil futures prices will decline gradually, and the Japanese economy will recover at a moderate pace. Amid continued significant wage increases, personal consumption is expected to remain resilient. In addition, the reduction in the consumption tax rate on food products starting in fiscal year 2027 is also expected to provide support for private consumption. The domestic cosmetics market is also expected to maintain a recovery trend, supported by positive factors such as rising wages.
Under these circumstances, in the anti-aging business, we aim to become a leading company in the anti-aging field, and under the concept of "Skin for Longevity," we will be expanding into the skincare field to better serve our customers in all aspects of their "skincare life." Specifically, we aim to deepen our connection with customers by enabling them to further experience the benefits of our products for their skin, not only in cleansing but across the entire skincare range, including lotions, serums, and emulsions. Furthermore, in order to enhance "Skin for Longevity," we will promote more active communication with our customers so that we can reflect their real voices in product planning and development more than ever before.
In addition, we will advance a sales strategy (channel mix) that integrates our own online store, e-commerce marketplaces, and physical stores, taking into account customer attributes, channel characteristics, and shifts in purchasing behavior; simultaneously, we will ensure high-quality, consistent communication (media mix) based on strategies designed to build our brand and increase awareness across multiple media channels.
Furthermore, we will analyze and improve our customer base to enhance the quality of our products and services, and leverage this customer base to provide new businesses, products, and services in the anti-aging field, aiming to diversify our revenue base and improve customer satisfaction.
In the recovery business, amidst intensifying competition driven by market growth, we will continue to focus on building a solid brand as a pioneer in the field. Furthermore, we will further strengthen collaboration within the Premier Anti-Aging Group to generate synergies. At the same time, we aim to drive sales growth by deepening our connections with customers through advertising, digital marketing, CRM, new product development, and store expansion.
With these endeavors, we expect to achieve consolidated net sales of 13,500 million yen (down 2.8% year-on-year), operating profit of 100 million yen (down 80.0% year-on-year), ordinary profit of 100 million yen (down 83.4% year-on-year) and profit attributable to owners of parent of 100 million yen (down 72.5% year on year) for the fiscal year ending July 31, 2027.

The earnings forecast and other forward-looking statements contained in this document are based on information currently available to, and certain assumptions that are deemed to be reasonable by the Group. Actual results may differ from the forecast due to various factors. The Company will promptly disclose any events that may affect the Group's business results.

2. Basic principle on the choice of accounting standards

The Group has adopted Japanese GAAP for accounting standards, in consideration of comparability of financial statements from period to period and between companies. As for the adoption of IFRS (International Financial Reporting Standards), the Group will appropriately consider it by taking into account the domestic and international circumstances.

3. Consolidated financial statements and major notes

(1) Consolidated balance sheet

(Millions of yen)

	Previous fiscal year (As of July 31, 2025)	Current fiscal year (As of July 31, 2026)
Assets		
Current assets		
Cash and deposits	4,655	4,951
Accounts receivable - trade	1,421	1,171
Finished goods	1,002	1,107
Raw materials and supplies	457	550
Prepaid expense	214	189
Other	321	326
Total current assets	8,073	8,297
Non-current assets		
Property, plant and equipment		
Buildings, net	414	437
Vehicles, net	0	4
Tools, furniture and fixtures, net	138	116
Total property, plant and equipment	553	559
Intangible assets		
Goodwill	310	268
Patent rights	169	151
Software	373	293
Software in progress	21	53
Other	39	36
Total intangible assets	914	802
Investments and other assets		
Investment securities	18	18
Long-term prepaid expenses	13	6
Deferred tax assets	81	96
Leasehold deposits	460	445
Other	63	55
Allowance for doubtful acconts	(37)	(37)
Total investments and other assets	599	584
Total non-current assets	2,067	1,947
Total assets	10,140	10,244

(Millions of yen)

	Previous fiscal year (As of July 31, 2025)	Current fiscal year (As of July 31, 2026)
Liabilities		
Current liabilities		
Accounts payable - trade	203	273
Short-term borrowings	405	860
Current portion of long-term borrowings	208	114
Current portion of bonds payable	26	17
Accounts payable - other	794	549
Income taxes payable	126	-
Accrued consumption taxes	75	-
Contract liabilities	163	263
Provision for bonuses	78	76
Provision for cotract loss	25	-
Provision for busuness structural reform	-	61
Other	890	649
Total current liabilities	2,997	2,865
Non-current liabilities		
Bonds payable	17	-
Long-term borrowings	451	383
Deferred tax liabilities	50	22
Asset retirement obligations	14	15
Total non-current liabilities	533	421
Total liabilities	3,530	3,287
Net assets		
Shareholders' equity		
Share capital	1,351	50
Capital surplus	1,351	2,653
Retained earnings	3,876	4,240
Treasury shares	(1)	(1)
Total shareholders' equity	6,578	6,942
Accumulated other comprehensive income		
Foreign currency translation adjustment	19	(15)
Total accumulated other comprehensive income	19	(15)
Stock acquisition rights	12	30
Total net assets	6,610	6,957
Total liabilities and net assets	10,140	10,244

(2) Consolidated statement of income and consolidated statement of comprehensive income

(Consolidated statement of income)

(Millions of yen)

	Previous fiscal year (From August 1, 2024 to July 31, 2025)	Current fiscal year (From August 1, 2025 to July 31, 2026)
Net sales	16,160	13,883
Cost of sales	3,774	3,327
Gross profit	12,386	10,556
Selling, general and administrative expenses	11,768	10,061
Operating profit	617	494
Non-operating income		
Interest income	3	9
Insurance contract refund	-	6
Profit on currency exchange	-	98
Miscellaneous income	12	15
Total non-operating income	15	128
Non-operating expenses		
Interest expenses	19	19
Loss on currency exchange	12	-
Miscellaneous losses	0	0
Total non-operating expenses	32	20
Ordinary profit	599	602
Extraordinary profit		
Gain on sale of non-current assets	-	2
Gain on sale of investment securities	20	-
Gain on reversal of stock acquisition rights	-	1
Total extraordinary profit	20	4
Extraordinary losses		
Loss on retirement of non-current assets	32	62
Restructuring costs	-	206
Total extraordinary losses	32	269
Profit before income taxes	588	337
Income taxes - current	139	7
Income taxes for prior periods	43	8
Income taxes - deferred	(66)	(43)
Total income taxes	116	(26)
Profit	471	364
Profit attributable to owners of parent	471	364

(Consolidated statement of comprehensive income)

(Millions of yen)

	Previous fiscal year (From August 1, 2024 to July 31, 2025)	Current fiscal year (From August 1, 2025 to July 31, 2026)
Profit	471	364
Other comprehensive income		
Foreign currency translation adjustment	1	(35)
Total other comprehensive income	1	(35)
Comprehensive income	473	328
Comprehensive income attributable to		
Owners of parent	473	328
Non-controlling interests	-	-

(3) Consolidated statement of changes in shareholders' equity

Previous fiscal year (From August 1, 2024 to July 31, 2025)

(Millions of yen)

	Shareholders' equity					Accumulated other comprehensive		Stock acquisition rights	Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Foreign currency translation adjustment	Total accumulated other comprehensive income		
Balance at beginning of period	1,351	1,351	3,404	(1)	6,106	17	17	-	6,124
Changes of items during period									
Profit attributable to owners of parent			471		471				471
Net changes in items other than shareholders' equity						1	1	12	13
Total changes of items during period	-	-	471	-	471	1	1	12	485
Balance at end of period	1,351	1,351	3,876	(1)	6,578	19	19	12	6,610

Current fiscal year (From August 1, 2025 to July 31, 2026)

(Millions of yen)

	Shareholders' equity					Accumulated other comprehensive income		Stock acquisition rights	Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Foreign currency translation adjustment	Total accumulated other comprehensive income		
Balance at beginning of period	1,351	1,351	3,876	(1)	6,578	19	19	12	6,610
Changes of items during period									
Profit attributable to owners of parent			364		364				364
Transfer from share capital to capital surplus	(1301)	1301			-				-
Net changes in items other than shareholders' equity						(35)	(35)	18	(16)
Total changes of items during period	(1,301)	1,301	364	-	364	(35)	(35)	18	347
Balance at end of period	50	2,653	4,240	(1)	6,942	(15)	(15)	30	6,957

(4) Consolidated statement of cash flows

(Millions of yen)

	Previous fiscal year (From August 1, 2024 to July 31, 2025)	Current fiscal year (From August 1, 2025 to July 31, 2026)
Cash flows from operating activities		
Profit before income taxes	588	337
Depreciation	257	259
Amortization of goodwill	41	41
Loss (gain) on sale of non-current assets	-	(2)
Loss (Gain) on sale of investment securities	(20)	-
Loss on retirement of non-current assets	32	62
Restructuring costs	-	206
Increase (decrease) in allowance for doubtful accounts	(39)	(0)
Increase (decrease) in provision for contract loss	(333)	(25)
Interest income	(3)	(9)
Interest expenses	19	19
Decrease (increase) in trade receivables	305	249
Decrease (increase) in inventories	125	(266)
Increase (decrease) in trade payables	(1)	69
Increase (decrease) in accounts payable - other	(62)	(255)
Increase (decrease) in accrued expenses	(44)	(39)
Decrease (increase) in prepaid expenses	37	24
Increase (decrease) in accrued consumption taxes	177	(95)
Other, net	296	(165)
Subtotal	1,376	410
Interest received	3	9
Interest paid	(19)	(19)
Income taxes (paid) or refunded	155	(173)
Income taxes paid for prior periods	(43)	(8)
Net cash provided by (used in) operating activities	1,472	217
Cash flows from investing activities		
Decrease (increase) in time deposits	7	-
Purchase of property, plant and equipment	(30)	(86)
Gain on sale of property, plant and equipment	-	3
Purchase of intangible assets	(165)	(155)
Proceeds from collection of loans	2	2
Payments of leasehold and guarantee deposits	(0)	(3)
Proceeds from collection of lease and guarantee deposits	2	0
Payments of insurance funds	(1)	(0)
Gain on surrender of insurance policy	-	13
Gain on sale of investment securities	21	-
Other	(64)	0
Net cash provided by (used in) investing activities	(229)	(227)
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	(603)	455
Proceeds from long term borrowings	-	50
Repayments of long-term borrowings	(707)	(211)
Payments of redemption of bonds	(26)	(26)
Net cash provided by (used in) financing activities	(1,337)	267
Effect of exchange rate changes on cash and cash equivalents	(3)	37
Net increase (decrease) in cash and cash equivalents	(98)	295
Cash and cash equivalents at beginning of period	4,753	4,655
Cash and cash equivalents at end of period	4,655	4,951

(5) Notes on consolidated financial statements
(Notes on going concern assumption)
Not applicable

(Notes on segment information, etc.)
[Segment information]
1. Overview of reporting segments
(1) Method of determining reporting segments
The Company's reporting segments are aggregates of the Company's constituent units according to certain standards. These components have separate financial information available and are subject to periodic review by the highest management decision-making body to determine resource allocation and evaluate performance.
Since the Company mainly evaluates business performance by consolidated subsidiary, this is the unit for identifying business segments. Reporting segments are determined by aggregating those business segments that have similarities in terms of economic characteristics, markets in which products and services are sold, types of customers, etc.
(2) Types of products and services belonging to each reporting segment
The main products and services handled by each segment are listed below.
・Anti-aging business
The business primarily manufactures and sells skin care, hair care, and inner care products, and includes brands such as DUO, CANADEL, and clayence.
・Recovery business
This business primarily manufactures and sells recovery wear through Venex Co., Ltd.

2, Calculation method for the amounts of sales, profit or loss, assets and other items for each reporting segment
The accounting methods for the reporting segments are in accordance with the accounting policies adopted for preparing the consolidated financial statements.
Reporting segment profits are based on operating profit.
Internal profit and transfers between segments are based on prevailing market prices.

3. Information on the amounts of sales, profit or loss, assets and other items for each reporting segment.
I. Previous fiscal year (From August 1, 2024 to July 31, 2025)

(Millions of yen)

	Reporting segment			Adjustment amount	Amount recorded in consolidated statement of income
	Anti-aging business	Recovery business	Total		
Sales					
Sales to external customers	12,926	3,233	16,160	-	16,160
Internal sales and transfers between segments	-	-	-	-	-
Total	12,926	3,233	16,160	-	16,160
Segment profit	408	208	617	-	617
Segment assets	7,835	2,305	10,140	-	10,140
Other items					
Depreciation	232	24	257	-	257
Amortization of goodwill	-	41	41	-	41
Increase in property, plant and equipment and intangible assets	204	23	228	-	228

II. Current fiscal year (From August 1, 2025 to July 31, 2026)

(Millions of yen)

	Reporting segment			Adjustment amount	Amount recorded in consolidated statement of income
	Anti-aging business	Recovery business	Total		
Sales					
Sales to external customers	10,349	3,533	13,883	-	13,883
Internal sales and transfers between segments	-	-	-	-	-
Total	10,349	3,533	13,883	-	13,883
Segment profit	660	(165)	494	-	494
Segment assets	7,651	2,593	10,244	-	10,244
Other items					
Depreciation	230	28	259	-	259
Amortization of goodwill	-	41	41	-	41
Increase in property, plant and equipment and intangible assets	223	82	306	-	306

[Related information]

Previous fiscal year From August 1, 2024 to July 31, 2025

1. Information by product and service

This information is omitted because similar information is disclosed in the segment information.

2. Information by region

(1) Sales

This information is omitted because sales to external customers in Japan exceed 90% of the net sales reported in the consolidated statement of income.

(2) Property, plant and equipment

This information is omitted because the amount of property, plant and equipment located in Japan exceeds 90% of the amount of property, plant and equipment shown on the consolidated balance sheet.

3. Information by major customer

(Millions of yen)

Name of customer	Sales	Related segments
IDA Ryogokudo Co., Ltd.	1,617	Anti-aging business

Current fiscal year From August 1, 2025 to July 31, 2026

1. Information by product and service

This information is omitted because similar information is disclosed in the segment information.

2. Information by region

(1) Sales

This information is omitted because sales to external customers in Japan exceed 90% of the net sales reported in the consolidated statement of income.

(2) Property, plant and equipment

This information is omitted because the amount of property, plant and equipment located in Japan exceeds 90% of the amount of property, plant and equipment shown on the consolidated balance sheet.

3. Information by major customer

(Millions of yen)

Name of customer	Sales	Related segments
IDA Ryogokudo Co., Ltd.	1,433	Anti-aging business

[Information on impairment losses on non-current assets by reporting segment]

Previous fiscal year (From August 1, 2024 to July 31, 2025)

Not applicable

Current fiscal year (From August 1, 2025 to July 31, 2026)

Not applicable

[Information on amortization and unamortized balance of goodwill by reporting segment]

Previous fiscal year (From August 1, 2024 to July 31, 2025)

(Millions of yen)

	Anti-aging business	Recovery business	Other	Elimination	Total
Amortization	-	41	-	-	41
Unamortized balance	-	310	-	-	310

Current fiscal year (From August 1, 2025 to July 31, 2026)

(Millions of yen)

	Anti-aging business	Recovery business	Other	Elimination	Total
Amortization	-	41	-	-	41
Unamortized balance	-	268	-	-	268

[Information on gain on negative goodwill by reporting segment]

Not applicable

(Per share information)

	Previous fiscal year (From August 1, 2024 to July 31, 2025)	Current fiscal year (From August 1, 2025 to July 31, 2026)
Net assets per share	756.65 yen	794.33 yen
Basic earnings (losses) per share	54.10 yen	41.77 yen
Diluted earnings per share	54.03 yen	41.77 yen

Notes: 1. The basis for calculating net assets per share is as follows.

(Millions of yen)

	Previous fiscal year (As of July 31, 2025)	Current fiscal year (As of July 31, 2026)
Total net assets	6,610	6,957
Amount deducted from total net assets	12	30
(of which stock acquisition rights)	(12)	(30)
Net assets related to common shares at the end of the period	6,598	6,926
Number of common shares used in the calculation of net assets per share at end of period	8,720,379 shares	8,720,379 shares

2. The basis for calculating basic earnings per share is as follows.

(Millions of yen)

	Previous fiscal year (From August 1, 2023 to July 31, 2024)	Current fiscal year (From August 1, 2024 to July 31, 2025)
Basic earnings per share		
Profit attributable to owners of parent	471	364
Amount not attributable to common shareholders	-	-
Profit attributable to owners of parent for common shares	471	364
Average number of common shares during period	8,720,379 shares	8,720,379 shares
Diluted earnings per share		
Adjustments to profit attributable to owners of parent	-	-
Number of common shares increased	11,118 shares	-
(of which stock acquisition rights)	(11,118 shares)	(-)
Overview of dilutive shares not included in the calculation of diluted earnings per share because they have no dilutive effect	-	-

(Notes on significant subsequent events)

Not applicable